関連する実験動画

Updated: Sep 8, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

COX-2は,JAK2 / STAT3シグナル伝達経路の活性化により,免疫回避を媒介し,乳がんにおける化学反応感受性を低下させます

Guohua Liu¹, Peng Liu¹, Kai Liang¹

¹Department of the Third General Surgery, Anyang Tumor Hospital, Anyang, China.

|September 6, 2025

まとめ

サイクロオキシゲナーゼ-2 (COX-2) は,JAK2 / STAT3経路を活性化することによって,乳がんの成長と薬剤耐性を促進します. COX- 2を阻害すると,がん細胞死亡とT細胞媒介による破壊が促進され,新たな治療戦略が提供される.

科学分野:

腫瘍学
分子生物学
免疫学

背景:

乳がんは女性で最も一般的な悪性腫瘍で深刻な健康問題です
薬剤耐性は癌治療における重要な障壁です
サイクロオキシゲナーゼ-2 (COX-2) はがんの免疫回避と化学抵抗に関与しているが,乳がんにおけるその正確な役割は完全に理解されていない.

研究の目的:

乳がんの進行と化学抵抗におけるCOX-2の役割を調査する.
JAK2/STAT3シグナル伝達経路がCOX-2媒介作用に関与するかを明らかにする.
乳がん細胞生存と免疫応答に対するCOX- 2の調節の影響を評価する.

主な方法:

乳がん組織と細胞におけるCOX-2発現が確認された.
COX-2のノックダウンと過剰発現を利用して,その機能的影響を研究した.
CD8+ T細胞と化学療法による腫瘍細胞生存の評価
経路の関与を調査するためにJAK2/STAT3阻害剤を使用した.

主要な成果:

乳がんではCOX- 2発現の上昇が観察された.
COX- 2のダウンレギュレーションは,アポトーシスの増加,増殖の減少,化学療法とT細胞攻撃に対する感受性の向上につながった.
これらの効果は,JAK2/ STAT3阻害剤によって軽減された.
JAK2/ STAT3経路のCOX-2活性化が免疫回避と化学抵抗を誘導することが確認された.

結論:

COX-2は乳がんの進行,免疫回避,化学抵抗を促進する上で重要な役割を果たします.
JAK2/ STAT3シグナル伝達経路は,COX- 2の腫瘍性機能の重要な媒介である.
COX-2とJAK2/STAT3経路を標的にすることは,乳がんに対する有望な治療戦略です.

キーワード:

COX-2 について JAK2/STAT3 について乳がん化学療法に対する感受性免疫回避

さらに関連する動画

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

関連する概念動画

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Interactions Between Signaling Pathways

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...